Targeted toxins in cancer immunotherapy

Devalingam Mahalingam, Michael J. Brumlik, Reinhard Waehler, David T. Curiel, Tyler J. Curiel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.

Original languageEnglish
Title of host publicationCancer Immunotherapy
Subtitle of host publicationParadigms, Practice and Promise
PublisherSpringer New York
Pages377-396
Number of pages20
Volume9781461447320
ISBN (Electronic)9781461447320
ISBN (Print)1461447313, 9781461447313
DOIs
StatePublished - May 1 2013

Fingerprint Dive into the research topics of 'Targeted toxins in cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Mahalingam, D., Brumlik, M. J., Waehler, R., Curiel, D. T., & Curiel, T. J. (2013). Targeted toxins in cancer immunotherapy. In Cancer Immunotherapy: Paradigms, Practice and Promise (Vol. 9781461447320, pp. 377-396). Springer New York. https://doi.org/10.1007/978-1-4614-4732-0_12